Companies: 49,246 Total Market Cap: 132610228579447.66

RVL Pharmaceuticals plc

OTC-RVLPQ
Healthcare Biotechnology
Rank #49128
Market Cap 111
Volume 134,185
Price 0
Change (%) 900.00%
Country or region Ireland Ireland

RVL Pharmaceuticals plc's latest marketcap:

111

As of 05/20/2025, RVL Pharmaceuticals plc's market capitalization has reached $111. According to our data, RVL Pharmaceuticals plc is the 49128th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 111
Revenue (ttm) 36.92 M
Net Income (ttm) -68,266,000
Shares Out 111.41 M
EPS (ttm) -0.70
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/14/2025
Market Cap Chart
Data Updated: 05/20/2025

RVL Pharmaceuticals plc's yearly market capitalization.

RVL Pharmaceuticals plc has seen its market value drop from $257.85 M to $111 since 2020, representing a total decrease of 100.00% and an annual compound decline rate (CAGR) of 96.46%.
Date Market Cap Change (%)
05/20/2025 $111 0%
12/31/2024 $111 -99.97%
12/29/2023 $334,218 -99.7%
12/30/2022 $111.05 M 23.46%
12/31/2021 $89.95 M -65.11%
12/31/2020 $257.85 M

Company Profile

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company focuses on addressing unmet medical needs in underserved patient populations, particularly in the ocular and medical aesthetics therapeutic areas.

Key Focus Areas

  • Ocular Therapeutics: Specializes in treatments for eye-related conditions.
  • Medical Aesthetics: Offers solutions for aesthetic and cosmetic medical needs.

Flagship Product

The company commercializes Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution designed to treat acquired blepharoptosis (low-lying eyelid) in adults.

Corporate Background

Formerly known as Osmotica Pharmaceuticals plc, the company rebranded to RVL Pharmaceuticals plc in January 2022.

Headquarters

RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey, with operations extending to the United States, Argentina, and Hungary.

Frequently Asked Questions

As of 05/20/2025, RVL Pharmaceuticals plc (including the parent company, if applicable) has an estimated market capitalization of $111 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

RVL Pharmaceuticals plc global market capitalization ranking is approximately 49128 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Ireland
Founded 0
IPO Date n/a
Employees 125
CEO Brian Markison
Sector Healthcare
Industry Biotechnology
Address 400 Crossing Boulevard
Bridgewater, 08807
United States
Website https://www.rvlpharma.com
People Also Watch
VRTX
447.18 900.00%
CSL Limited
158.78 900.00%
REGN
614.79 900.00%
KRX-207940
732.25 900.00%